Long-term Safety of ketoconazole foam, 2%, in the treatment of seborrheic dermatitis: Results of a phase IV, open-label study

Journal of Drugs in Dermatology

Volumn 12, Issue 1, 2013, Pages

  Draelos, Zoe D ^a   Feldman, Steven R ^b   Butners, Victoria ^c   Saenz, Alessandra B Alió ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; KETOCONAZOLE;

ADOLESCENT; ADULT; AGED; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTICLE; CHILD; COUGHING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRURITUS; RHINOPHARYNGITIS; SCHOOL CHILD; SEBORRHEIC DERMATITIS; SIDE EFFECT; SINUSITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHILD; CHRONIC DISEASE; DERMATITIS, SEBORRHEIC; ENDPOINT DETERMINATION; ETHNIC GROUPS; FEMALE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT PREFERENCE; PHARMACEUTICAL VEHICLES; SAMPLE SIZE; SEX FACTORS; YOUNG ADULT;

EID: 84873469470     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Berk T, Scheinfeld N. Seborrheic dermatitis. P T. 2010;35(6):348-352.
2. Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin. 2003;21(3):401-412.
3. Zisova LG. Malassezia species and seborrheic dermatitis. Folia Med (Plovdiv). 2009;51(1):23-33
4. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38(8):628-632.
5. Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol. 2000;39(7):535-538.
6. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221-224.
7. Extina Foam [package insert]. Research Triangle Park, NC: Stiefel Laboratories, Inc; 2007. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2007/021738lbl.pdf. Accessed August 13, 2012.
8. Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 2006;5(7):646-650.
9. Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6(10):1001-1008.
10. Piérard-Franchimont C, Piérard GE, Arrese JE, De Doncker P. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology. 2001;202(2):171-176.
11. Jones-Caballero M, Pedrosa E, Peñas PF. Self-reported adherence to treatment and quality of life in mild to moderate acne. Dermatology. 2008;217(4):309-314.